Companies · Biotechnology

nContact Surgical Inc

Morrisville · Biotechnology

Diligence memoA one-page analyst read on nContact Surgical Inc — recommendation, valuation, rhythm, risks.
$50.3M
Total raised · real
8
Rounds
15.5×
Latest step-up
Top 19%
Sector rank · raised
Series B
Latest stage · inferred · Fri Mar 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

nContact Surgical Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.37× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

nContact Surgical Inc is one of 4293 Biotechnology companies tracked from Morrisville. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2009-04-09 Raised $4.8M (real) Modeled valuation $173M (est)Series A2009Series A · 2010-02-10 Raised $4.0M (real) Modeled valuation $145M (est)Series A2010Series A · 2010-02-10 Raised $3.0M (real) Modeled valuation $108M (est)Series A2010Series A · 2010-02-10 Raised $2.0M (real) Modeled valuation $72M (est)Series A2010Series B · 2010-10-20 Raised $16M (real) Modeled valuation $641M (est)Series B2010Series A · 2010-10-20 Raised $13M (real) Modeled valuation $476M (est)Series A2010Series B · 2011-12-21 Raised $434K (real) Modeled valuation $17M (est)Series B2011Series B · 2013-03-01 Raised $6.7M (real) Modeled valuation $267M (est)Series B2013+$4.0M+$3.0M+$2.0M+$16M+$13M+$434K+$6.7MCumulative $50M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.8M · 2009
Series A extension$4.0M · 2010
Series A extension$3.0M · 2010
Series A extension$2.0M · 2010
Series B$16.2M · 2010
Bridge · Series B-stage$13.2M · 2010smaller follow-on
Series B extension$434K · 2011
Series B extension$6.7M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$267.3M
Base estimate est.
$13.5M
Conservative case
$1.0B
Upside case
$37.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $173.0M · 2009-04-092009Series A · modeled $144.6M · 2010-02-10Series A · modeled $108.5M · 2010-02-10Series A · modeled $72.3M · 2010-02-10Series B · modeled $641.1M · 2010-10-20Series A · modeled $475.5M · 2010-10-20Series B · modeled $17.2M · 2011-12-21Series B · modeled $267.3M · 2013-03-012013
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
13.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$12.9M/yr
Capital velocity
17.2 yr
On record since
2009
First round
8
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.0× above median
This company$50.3M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.4× of median
This company$6.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 4.2× above median
This company$267.3M
Sector median$64.2M

Raised more than 82% of sector peers (real $). Modeled value above 75% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #59 of 77.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)BioAtla,LLC · Series B Raised $47.9M · modeled $1.5B (est)Scholar Rock LLC · Series B Raised $36.3M · modeled $1.4B (est)Oligasis, LLC · Series B Raised $35.8M · modeled $1.3B (est)Alector LLC · Series B Raised $32.3M · modeled $1.3B (est)Gelesis Inc · Series B Raised $37.7M · modeled $1.3B (est)Prosetta Biosciences Inc. · Series B Raised $31.1M · modeled $1.2B (est)Stem Cell Therapeutics Corp · Series B Raised $30.3M · modeled $1.2B (est)Tenex Health, Inc. · Series B Raised $57.4M · modeled $1.2B (est)Aquesys Inc · Series B Raised $49.5M · modeled $1.2B (est)4Tech, Inc. · Series B Raised $62.3M · modeled $1.1B (est)Lorus Therapeutics Inc · Series B Raised $28.3M · modeled $1.1B (est)Kallyope, Inc. · Series B Raised $28.1M · modeled $1.1B (est)nContact Surgical Inc (this company) Raised $50.3M · modeled $267.3M (est)nContact Surgical Inc
CompanyStageRaised · realValue · estvs peer med.
BioAtla,LLCSeries B$47.9M$1.5B2.16×
Scholar Rock LLCSeries B$36.3M$1.4B2.01×
Oligasis, LLCSeries B$35.8M$1.3B1.88×
Alector LLCSeries B$32.3M$1.3B1.79×
Gelesis IncSeries B$37.7M$1.3B1.75×
Prosetta Biosciences Inc.Series B$31.1M$1.2B1.73×
Stem Cell Therapeutics CorpSeries B$30.3M$1.2B1.68×
Tenex Health, Inc.Series B$57.4M$1.2B1.66×
Aquesys IncSeries B$49.5M$1.2B1.66×
4Tech, Inc.Series B$62.3M$1.1B1.60×
Lorus Therapeutics IncSeries B$28.3M$1.1B1.57×
Kallyope, Inc.Series B$28.1M$1.1B1.56×
nContact Surgical Inc this companySeries B$50.3M$267.3M0.37×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.8M2009-04-09$21.8M$173.0M90%
Series A$4.0M2010-02-10$18.2M$144.6M90%
Series A$3.0M2010-02-10$13.6M$108.5M90%
Series A$2.0M2010-02-10$9.1M$72.3M90%
Series B$16.2M2010-10-20$89.7M$641.1M90%
Series A$13.2M2010-10-20$59.8M$475.5M90%
Series B$434K2011-12-21$2.4M$17.2M90%
Series B$6.7M2013-03-01$37.4M$267.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.8M2009-04-09
    • First recorded raise — entered as Series A.
  2. Series A$4.0M2010-02-10
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  3. Series A$3.0M2010-02-10
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
  4. Series A$2.0M2010-02-10
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
  5. Series B$16.2M2010-10-20
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 8.1× larger than the prior — scaling up.
  6. Series A$13.2M2010-10-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  7. Series B$434K2011-12-21
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 30.3× smaller than the prior — bridge or down round.
  8. Series B$6.7M2013-03-01
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 15.5× larger than the prior — scaling up.
Intelligence
2013 ~Q3
Modeled next raise · ~7mo cadence
$20.2M
Modeled next size est.range $13.1M$32.3M
15.5×
Last step-up
$12.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Dennis Dougherty3 other2009-04
William W Brooke3 other2011-12
Bruce J Brumfield2 other2010-02
Dennis J. Dougherty2 other2010-10
Jay Brumfield1 other2009-04
John P Funkhouser1 other2010-02
Nathalie Greene1 other2009-04
Dennis D Dougherty2010-02
James G Whayne2010-02
James Whayne2009-04
John D. Uhrin2010-02
John Funkhouser2009-04
John P. Uhrin2010-10
John Uhrin2009-04
Michael D Estes2011-12
Michael Estes2009-04
Michael J. Estes2010-02
Michael P. Estes2010-10
Nathalie D Greene2010-02
Robert J Young2010-10
Sidney D Fleischman2010-02
Sidney Fleischman2009-04
William D. Brooke2013-03
William D. Earthman2010-02
Registry & provenance

nContact Surgical Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1376563
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
BIND Biosciences IncBiotechnologySeries B$51.4M$345.2Msame sector · same stage
Minerva Neurosciences, Inc.BiotechnologySeries B$52.0M$219.6Msame sector · same stage
Nectero Medical IncBiotechnologySeries B$52.5M$259.4Msame sector · same stage
Noetik Inc.BiotechnologySeries B$48.0M$275.5Msame sector · same stage
Riot Blockchain, Inc.BiotechnologySeries B$53.0M$280.2Msame sector · same stage
Gennao Bio, Inc.BiotechnologySeries B$47.5M$211.8Msame sector · same stage
Ocunexus Therapeutics, Inc.BiotechnologySeries B$53.2M$292.6Msame sector · same stage
Mythic Therapeutics, Inc.BiotechnologySeries B$53.5M$176.4Msame sector · same stage
Frequently asked
How much funding has nContact Surgical Inc raised?
nContact Surgical Inc has raised approximately $50.3M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is nContact Surgical Inc's estimated valuation?
Provath's modeled valuation for nContact Surgical Inc is approximately $267.3M (modeled range $13.5M–$1.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is nContact Surgical Inc at?
nContact Surgical Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Mar 01.
What does nContact Surgical Inc do and where is it based?
nContact Surgical Inc operates in the Biotechnology sector, based in Morrisville.
Explore related

See where nContact Surgical Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at nContact Surgical Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.